- Expanded AVIEW portfolio spans lung and cardiovascular analysis, supported by 13 U.S. FDA 510(k) clearances
- Drawing on lung cancer screening experience across Germany, France, and Italy to highlight the shift from AI detection to real-world clinical implementation
CHICAGO and SEOUL, South Korea, Nov. 19, 2026 /PRNewswire/ -- Coreline Soft, a medical artificial intelligence (AI) company, will participate in RSNA 2026, taking place from November 29 to December 3 at McCormick Place in Chicago. The company will showcase its chest CT-based AI platform, AVIEW, at Booth #5135 in the AI Showcase (South Hall, Level 3).
At the exhibition, Coreline Soft will present its core product portfolio, including AVIEW LCS and AVIEW Lung Nodule CAD for lung nodule detection and analysis; AVIEW COPD for emphysema and chronic obstructive pulmonary disease (COPD) assessment; AVIEW CAC for coronary artery calcium quantification; and AVIEW Aorta Metrics for aortic measurement. Following the recent U.S. FDA 510(k) clearance of AVIEW Aorta Metrics, Coreline Soft now holds a total of 13 FDA 510(k) clearances.
Coreline Soft's "One CT, Multi-Disease" strategy aims to maximize the clinical value of a single chest CT scan by quantitatively analyzing multiple biomarkers including lung nodules, emphysema, coronary artery calcification, and aortic dimensions. Beyond single-disease detection, the strategy aims to expand the range of clinically relevant insights from existing CT scans and support their integration into routine care and screening workflows.
Meanwhile, RSNA 2026 will feature a range of studies by researchers from Korea and abroad using the AVIEW platform. Research topics range widely, from a large-scale validation study that estimates pulmonary function from a single chest CT scan and compares it with spirometry, to the classification of normal, PRISm, and COPD cohorts, longitudinal tracking of interstitial lung disease before and after treatment, quantitative evaluation of occupational lung diseases such as coal workers' pneumoconiosis, and evaluation of the consistency of AI-based lung nodule analysis across different imaging conditions. It is also noteworthy that AVIEW is being used in studies addressing a variety of diseases and clinical questions at the world's largest radiology meeting. This reflects AVIEW's expanding role across academic research as an imaging analysis platform that quantifies lung structure and function, going beyond lesion detection.
The adoption of AVIEW across such diverse clinical studies at one of the world's premier radiology conferences underscores its evolution expanding beyond simple lesion detection into a comprehensive quantitative imaging platform for evaluating both lung structure and function.
In the United States, demand is accelerating for opportunistic screening and quantitative imaging biomarkers that derive additional health insights from routine CT scans. Addressing this trend, Coreline Soft is advancing PACS-based "Zero-Click" workflow automation with INFINITT North America and extending its strategic collaboration with 3DR Labs for a fourth consecutive year.
The company is also partnering with U.S. firms to build integrated solutions that combine lung nodule detection with malignancy risk assessment, supporting the full continuum of care from early detection to follow-up management. Furthermore, Coreline Soft is developing commercial models aligned with the U.S. reimbursement landscape as well as public and community healthcare sectors, laying a stronger foundation for local market expansion.
In Europe, Coreline Soft continues to expand its presence in lung cancer screening across key markets, including Germany, France, and Italy. In Germany, AVIEW LCS Plus and AVIEW HUB support multicenter screening workflows, integrating AI-assisted nodule analysis with secure imaging data exchange, primary and secondary reading coordination, and longitudinal follow-up management.
Currently deployed across more than 500 clinical sites across 19 countries, AVIEW has surpassed 3 million cumulative analyses. Under the theme "From AI Detection to Clinical Implementation," Coreline Soft will demonstrate at RSNA 2026 how its quantitative imaging technologies are actively transforming radiology workflows and national screening programs worldwide.
SOURCE Coreline Soft

Share this article